Abstract

Colorectal cancer (CRC) survivors completing curative treatment require post-treatment surveillance for potential disease recurrence. Clinical guidelines recommend carcinoembryonic antigen (CEA) testing every three to six months over a five-year period, with little guidance on who should return for testing within three months versus waiting longer. This study aims to identify key patient and physician characteristics that predict the likelihood of frequent CEA testing in current practice. Understanding real-world surveillance patterns may help enhance post-treatment care for CRC survivors.